NASDAQ:DNLI - Denali Therapeutics Price Target & Analyst Ratings

Sign in or create an account to add this stock to your watchlist.
$19.45 -0.87 (-4.28 %)
(As of 03/22/2019 04:00 PM ET)
Previous Close$19.45
Today's Range$19.3350 - $20.8089
52-Week Range$12.32 - $25.05
Volume490,564 shs
Average Volume496,945 shs
Market Capitalization$1.85 billion
P/E Ratio-49.87
Dividend YieldN/A

Analyst Ratings

Denali Therapeutics (NASDAQ:DNLI) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Denali Therapeutics in the last 12 months. Their average twelve-month price target is $25.50, suggesting that the stock has a possible upside of 31.11%. The high price target for DNLI is $26.00 and the low price target for DNLI is $25.00. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.502.832.75
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $25.50$25.50$24.60$24.00
Price Target Upside: 31.11% upside19.33% upside29.88% upside53.45% upside

Denali Therapeutics (NASDAQ:DNLI) Consensus Price Target History

Price Target History for Denali Therapeutics (NASDAQ:DNLI)

Denali Therapeutics (NASDAQ:DNLI) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/29/2019Cantor FitzgeraldDowngradeOverweight ➝ Neutral$25.00HighView Rating Details
11/12/2018Janney Montgomery ScottInitiated CoverageBuy ➝ Buy$26.00LowView Rating Details
1/2/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$23.00MediumView Rating Details
1/2/2018Goldman Sachs GroupInitiated CoverageNeutral ➝ NeutralHighView Rating Details
1/2/2018Morgan StanleyInitiated CoverageOverweight ➝ Overweight$25.00HighView Rating Details
1/2/2018JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$24.00HighView Rating Details
(Data available from 3/23/2017 forward)
This page was last updated on 3/23/2019 by Staff

Featured Article: What is the NASDAQ?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel